lansoprazole has been researched along with Esophageal Neoplasms in 6 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment of Barrett's esophagus is controversial." | 2.43 | [The clinical strategy for the Barrett's esophagus]. ( Goto, H; Kitabatake, S; Niwa, Y, 2005) |
| "The length of the Barrett's esophagus segment and the size of a hiatal hernia are associated with the risk of developing high-grade dysplasia and esophageal adenocarcinoma." | 2.42 | Reflux disease and Barrett's esophagus. ( Haag, S; Holtmann, G, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miura, M | 1 |
| Motoyama, S | 1 |
| Hinai, Y | 1 |
| Niioka, T | 1 |
| Endo, M | 1 |
| Hayakari, M | 1 |
| Ogawa, J | 1 |
| Okamura, Y | 1 |
| Takeno, S | 1 |
| Takahashi, Y | 1 |
| Moroga, T | 1 |
| Yamashita, S | 1 |
| Kawahara, K | 1 |
| Miyashita, T | 1 |
| Shah, FA | 1 |
| Harmon, JW | 1 |
| Marti, GP | 1 |
| Matsui, D | 1 |
| Okamoto, K | 1 |
| Makino, I | 1 |
| Hayashi, H | 1 |
| Oyama, K | 1 |
| Nakagawara, H | 1 |
| Tajima, H | 1 |
| Fujita, H | 1 |
| Takamura, H | 1 |
| Murakami, M | 1 |
| Ninomiya, I | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Ohta, T | 1 |
| Haag, S | 1 |
| Holtmann, G | 1 |
| Kitabatake, S | 1 |
| Niwa, Y | 1 |
| Goto, H | 1 |
| Cooper, BT | 1 |
| Chapman, W | 1 |
| Neumann, CS | 1 |
| Gearty, JC | 1 |
3 reviews available for lansoprazole and Esophageal Neoplasms
| Article | Year |
|---|---|
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esop | 2013 |
Reflux disease and Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Endos | 2003 |
[The clinical strategy for the Barrett's esophagus].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Ba | 2005 |
3 other studies available for lansoprazole and Esophageal Neoplasms
| Article | Year |
|---|---|
Influence of CYP2C19 and ABCB1 polymorphisms on plasma concentrations of lansoprazole enantiomers after enteral administration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette T | 2010 |
Refractory ulcer of reconstructed gastric tube after esophagectomy: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Carcinoma, Squamous Cell; Cy | 2013 |
Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Barrett Eso | 2006 |